Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
04 oct. 2023 07h00 HE
|
Freeline Therapeutics Holdings plc
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
15 août 2023 07h00 HE
|
Freeline Therapeutics Holdings plc
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase...
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
08 août 2023 07h30 HE
|
Freeline Therapeutics Holdings plc
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August...
Freeline to Participate in Upcoming Investor Conferences
31 juil. 2023 07h30 HE
|
Freeline Therapeutics Holdings plc
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company will be participating in two upcoming investor conferences in August....
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
25 juil. 2023 07h30 HE
|
Freeline Therapeutics Holdings plc
LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced it will host a virtual Key Opinion Leader (KOL) event on FLT201, its adeno-associated...
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
26 juin 2023 07h30 HE
|
Freeline Therapeutics Holdings plc
FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant of GCase, the enzyme missing in people with Gaucher disease Company expects to report...
Freeline Reports First Quarter 2023 Financial Results and Business Highlights
30 mai 2023 07h30 HE
|
Freeline Therapeutics Holdings plc
Expect to report initial clinical data for FLT201 in Gaucher disease in third quarter of 2023 FLT201 granted ILAP designation, which aims to accelerate time to market and facilitate patient access in...
Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease
22 mai 2023 08h00 HE
|
Freeline Therapeutics Holdings plc
LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease...
Freeline Completes ADS Ratio Change
12 mai 2023 08h05 HE
|
Freeline Therapeutics Holdings plc
LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company’s previously disclosed change to its American Depositary Share (“ADS”) to...
Freeline Announces Proposed ADS Ratio Change
21 avr. 2023 07h00 HE
|
Freeline Therapeutics Holdings plc
LONDON, April 21, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its...